M&A Deal Summary

Takara Bio Acquires Takara Bio USA Holdings

On July 1, 2005, Takara Bio acquired medical products company Takara Bio USA Holdings from Becton Dickinson for 60M USD

Acquisition Highlights
  • This is Takara Bio’s 1st transaction in the Medical Products sector.
  • This is Takara Bio’s largest (disclosed) transaction.
  • This is Takara Bio’s 1st transaction in the United States.
  • This is Takara Bio’s 1st transaction in California.

M&A Deal Summary

Date 2005-07-01
Target Takara Bio USA Holdings
Sector Medical Products
Buyer(s) Takara Bio
Sellers(s) Becton Dickinson
Deal Type Divestiture
Deal Value 60M USD

Target

Takara Bio USA Holdings

Mountain View, California, United States
website
Takara Bio USA Holdings, Inc. is a provider of kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takara Bio

Kusatsu, Japan

website


Category Company
Founded 2002
Sector Life Science
Employees1,666
Revenue 67.7B JPY (2022)
DESCRIPTION

Takara Bio is a biotechnology company, that provides biotechnology research and development. Takara Bio active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Takara Bio was founded in 2002 and is based in Kusatsu, Japan.


DEAL STATS #
Overall 1 of 3
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 2
State (California) 1 of 2
Country (United States) 1 of 2
Year (2005) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-29 Cellectis AB

Gothenburg, Sweden

Cellectis AB is a biotechnology company focused on applications of human embryonic stem cell (HES) based products and technologies for the industry and the research community.

Buy -

Seller(S) 1

SELLER

Becton Dickinson

Franklin Lake, New Jersey, United States

website


Category Company
Founded 1897
Sector Medical Products
Employees75,000
Revenue 18.9B USD (2022)
DESCRIPTION

Becton Dickinson is a global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Becton Dickinson was incorporated in 1897 and is headquartered in Franklin Lake, New Jersey.


DEAL STATS #
Overall 1 of 8
Sector (Medical Products) 1 of 7
Type (Divestiture) 1 of 8
State (California) 1 of 1
Country (United States) 1 of 8
Year (2005) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-07-01 Atto BioScience

Rockville, Maryland, United States

Atto Bioscience, a privately held Maryland-based company, specializes in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. These products and technologies are targeted at the emerging field of high content cell analysis that is rapidly taking hold in the pharmaceutical, biotechnology, academic, and government research markets.

Buy $25M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-01-10 GeneOhm Sciences

San Diego, California, United States

GeneOhm Sciences, Inc., a pioneer in the development of molecular diagnostic testing for the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs), a growing global healthcare problem.

Buy -